Thera-SAbDab

SIFALIMUMAB

> Structural Summary

Therapeutic	Sifalimumab
Target	IFNA1
Heavy Chain	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYSISWVRQAPGQGLEWMGWISVYNGNTNYAQKFQGRVTMTTDTSTSTAYLELRSLRSDDTAVYYCARDPIAAGYWGQGTLVTVSS
Light Chain	EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKVEIK
100% seqID Fv Structure	4ypg [Fvs: BA, HL]
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

100% seqID Structure	4ypg [Fvs: BA, HL]

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb
Isotype	G1
Highest Clinical Trial (June '19)	Phase-II
Estimated Status (June '19)	Discontinued
Recorded Developmental Technology	na
INN Year Proposed	2009
INN Year Recommended	2010
Companies Involved	Medarex, MedImmune
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Myositis, Psoriasis, Systemic lupus erythematosus
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]